Unveiling the theranostic potential of SPIONs in Alzheimer's disease management

• Published in: Journal of psychiatric research 2024-11, Vol.179, p.244-256
• Main Authors: Aminyavari, Samaneh, Afshari, Amir R., Ahmadi, Seyed Sajad, Kesharwani, Prashant, Sanati, Mehdi, Sahebkar, Amirhossein
• Format: Article
• Language: English
• Subjects: Alzheimer Disease - diagnosis; Alzheimer Disease - drug therapy; Alzheimer Disease - therapy; Alzheimer's disease; Amyloid beta-Peptides - metabolism; Amyloid-beta; Animals; Diagnostic option; Humans; Magnetic Iron Oxide Nanoparticles; Superparamagnetic iron oxide nanoparticle; Theranostic Nanomedicine
• ISSN: 0022-3956; 1879-1379; 1879-1379
• DOI: 10.1016/j.jpsychires.2024.09.022

Alzheimer's disease (AD) is a devastating kind of dementia that is becoming more common worldwide. Toxic amyloid-beta (Aβ) aggregates are the primary cause of AD onset and development. Superparamagnetic iron oxide nanoparticles (SPIONs) have received a lot of interest in AD therapy over the last decade because of their ability to redirect the Aβ fibrillation process and improve associated brain dysfunction. The potential diagnostic application of SPIONs in AD has dramatically increased this interest. Furthermore, surface-modified engineered SPIONs function as drug carriers to improve the efficacy of current therapies. Various preclinical and clinical studies on the role of SPIONs in AD pathology have produced encouraging results. However, due to their physicochemical properties (e.g., size, surface charge, and particle concentration) in the biological milieu, SPIONs may play the role of a preventive or accelerative agent in AD. Even though SPIONs are potential therapeutic and diagnostic options in AD, significant efforts are still needed to overcome the inconsistencies and safety concerns. This review evaluated the current understanding of how various SPIONs interact with AD models and explored the discrepancies in their efficacy and safety.